Apixaban

Chemical formula: C₂₅H₂₅N₅O₄ Molecular mass: 459.497 g/mol PubChem compound: 10182969

Therapeutic indications

Apixaban is indicated for:

Prevention of venous thromboembolic events in elective hip or knee replacement surgery

Population group: only adults (18 years old or older)

Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2.5 mg twice daily

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF)

Population group: only adults (18 years old or older)

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

5 mg twice daily

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)

Population group: only adults (18 years old or older)

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg twice daily for the first 7 days followed by 5 mg twice daily

Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)

Population group: only adults (18 years old or older)

Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2.5 mg twice daily

Treatment of venous thromboembolism (VTE)

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Treatment of venous thromboembolism (VTE) in paediatric patients from 28 days to less than 18 years of age.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.6-10 mg twice daily based on body weight for Days 1-7 and from Day 8 and beyond 0.3-5 mg twice daily based on body weight

Prevention of recurrent venous thromboembolism (VTE)

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Prevention of recurrent venous thromboembolism (VTE) in paediatric patients from 28 days to less than 18 years of age.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.6-10 mg twice daily based on body weight for Days 1-7 and from Day 8 and beyond 0.3-5 mg twice daily based on body weight

Contraindications

Apixaban is contraindicated in the following cases:

Anticoagulants

Antithrombotic agents

Lactation

Lactation

Active clinically significant bleeding

Bleeding

Lesion or condition, if considered a significant risk factor for major bleeding

at least one of

Gastrointestinal ulcer
Spinal injury
Traumatic brain injury
Intracranial hemorrhage
Operation on brain
Operative procedure on spinal structures
Esophageal varices
Aneurysm
Congenital vascular malformation

Hepatic disease clinically relevant bleeding risk

at least one of

Hepatic insufficiency and additionally High risk of hemorrhage

Blood coagulation disorder due to liver disease

Surgery and invasive procedures

at least one of

Surgical procedure
Procedure on cardiovascular system
Catheterization

Spinal/epidural anaesthesia or puncture

at least one of

Spinal block
Epidural anesthesia
Lumbar puncture

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈